Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

Why Prurisol is worth at least $10 Billion!!!

At 300 mg per day and 400 mg per day Prurisol as an inexpensive and convenient oral drug will capture more of the market share now held by more expensive biologic treatments that currently are estimated to be over $8 billion per year.

Prurisol is worth at least twice what Otezla is worth!!!

Look up net present value which considers the years of revenues of say $6 billion each and every year for over a decade.

Also, Prurisol will be effective for other inflammatory diseases and conditions including arthritis including psoriatic arthritis, rheumatoid arthritis, osteoarthritis, multiple myeloma, etc.

Comments from the principle investigators from the previously completed Prurisol Phase 2a trial:

Investigator Comments
Cellceutix would also like to share some observations and comments from Principle Investigators (PIs) overseeing different participating clinical sites in the trial. Numerous PIs noted patients expressed a desire to have access to Prurisol following the study's conclusion. Moreover, the Company learned that some patients were previously unsuccessfully treated with other therapies, including biologics and apremilast (Otezla®).
Included below is a sampling of responses that were authorized to be published:
"Well designed study, patients were pleased, minimal to no side effects."
"Good tolerability was shown with very few AEs reported. Good compliance and good patient satisfaction."
"Overall impression of the study is very positive, as well as the patients' satisfaction."
When asked, "Why would you choose Prurisol (should it be approved) over another oral compound for psoriasis?" and "Why would you choose Prurisol over an injectable biologic?" responses included:
"Because [Prurisol] does not cause any severe side effects. Patients dislike needles and injections because they cause pain and discomfort."
"Patients overall prefer oral medications over injectable medication. Our experience with injectable studies for other indications has been that many subjects do not like taking them and those studies tend to be difficult compared to oral medications to recruit subjects."
"Because of [Prurisol's] low side effect profile."
"Patients prefer oral treatments."

FIG. 6 shows appearance of skin by naked eye in psoriatic animals and those treated with Prurisol.

“Mice treated with Prurisol showed no reoccurrence of psoriatic lesions during the experiment, whereas animals treated with MTX showed a median reoccurrence of lesions by the 57th day.”

https://www.google.com/patents/US20140200229

The Psoriasis Market
Psoriasis is a chronic, non-infectious, immune-mediated inflammatory skin disorder, characterized by well-defined salmon-pink lesions on the scalp, trunk and extensor surfaces that are itchy and scaly. While the cause of psoriasis is still unknown, there is often a genetic predisposition and it is commonly triggered by environmental factors. Multiple medical comorbidities have been linked to psoriasis, such as psoriatic arthritis, metabolic syndrome, diabetes and cardiovascular disease.

Psoriasis can range from mild, moderate to severe disease and affects approximately 3% of the world’s population, or about 125 million people, with onset typically between the ages of 15 to 25 years – although psoriasis can develop at any age. The incidence of psoriasis is dependent on the climate and genetic heritage of the population, with prevalence increasing in colder climates and in those with lighter skin. It is estimated that over 9 million people in the US suffer from psoriasis. Recent estimates indicate a global market size of $8 billion for psoriasis, comprising about 34% of all dermatological drug sales.

Topical agents, such as corticosteroids and vitamin D analogues, are typical first-line therapies for patients with mild psoriasis, although side effects are a primary concern for chronic use and these treatments are generally ineffective for patients with more severe cases. The psoriasis landscape is largely dominated by IL-17 targeted biologics aimed at patients with moderate-to-severe disease, with the top four biologic agents generating approximately $6 billion in global sales. Current gold standard biologic therapies are costly and have potential to cause significant side effects, with their longer-term safety yet to be fully classified. Due to the large therapeutic gap between first-line and biological remedies, and the side-effect profile of existing topical agents, the need for safer and well-tolerated medicines still exists.

http://www.brickellbio.com/psoriasis.html

Good luck and GOD bless,

George